CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

CD19 and CD22 Targeted CAR-T Therapy is under clinical development by Chongqing Precision Biotech and currently in Phase II for Unspecified B-Cell Lymphomas.

Umoja Biopharma has secured $100 million in series C funds as the cancer-focused biotech looks to bring more of its cell ...

In a cohort of more than 300 patients with relapsed or refractory disease, 99.1% treated with the CD19/CD22-directed product bicistronic achieved a complete remission or complete remission with ...

CD19, a B-cell surface protein, is expressed across B-cell development and it is expressed on almost all B-cell malignancies, such as ALL, chronic lymphocytic leukemia (CLL) and several non ...

In CAR-T therapy, CD19 is now the most extensively used target. It has been confirmed to be effective and safe for the treatment of CLL, B-ALL and B cell lymphoma. FMC63, an IgG2a mouse monoclonal ...